April 12, 2021 – ZOLL Medical Corporation, an Asahi Kasei company, announced it has acquired Respicardia, Inc., a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA).
Respicardia’s remedē System, a treatment for CSA, is the only implantable device approved by the U.S. Food and Drug Administration (FDA) to treat moderate to severe CSA in adult patients with reduced cardiac function.
According to the company, CSA results in shallow or disrupted breathing during sleep, and many patients with CSA also have heart disease, especially heart failure. Within this population, patients with CSA are at increased risk for hospitalizations and even death.
ZOLL, which has been a significant investor in Respicardia for more than three years, will welcome all Respicardia employees into its global workforce, and will maintain Respicardia’s current headquarters in Minnetonka, Minnesota.